Major depressive disorder (MDD) is the most common mood disorder, with a lifetime prevalence in the general population of almost 20%. Depression is a debilitating illness that can cause severe functional impairment and emotional anguish. It is associated with significant income loss, absenteeism from work, and increased health care system costs. Depression appears to be particularly common in general medical settings. Current rates of depressive conditions ranging from 15% to 21% are reported in primary care populations. However, depression in primary care settings is often unrecognized and untreated.

Depression may exacerbate symptoms of chronic general medical conditions and is associated with poor outcome in patients with diabetes, hypertension, and coronary artery disease. Frasure-Smith et al. reported that depression was a significant predictor of post–myocardial infarction mortality. Several studies of diabetic patients have linked depression to poor glucose control, higher glycosylated hemoglobin values, increased reporting of both hyperglycemic and hypoglycemic symptoms, and increased rates of complications.

The presence of a general medical illness may also adversely affect the course of depressive disorders. Depressed diabetic patients were found to have 8 times the rate of depression relapse of depressed persons who were physically healthy. Numerous studies have shown that psychiatric symptoms in depressed patients with general medical illnesses appear to improve in response to antidepressant therapy. Imipramine improved mood in depressed patients with the human immunodeficiency virus. Nortriptyline therapy was associated with improvement in depressive symptoms compared with placebo in diabetic patients.

As are diabetes mellitus and coronary artery disease, asthma is a common, chronic, and debilitating general medical condition. Data suggest that the prevalence of asthma and asthma-related morbidity and mortality has increased in the past 2 decades. Asthma has long been considered an illness in which mood and emotions contribute to symptom exacerbation. Therefore, we reviewed the recent literature on depression in persons with asthma.

**Data Sources:** The MEDLINE (1966–1999) and PSYCHINFO (1967–1999) databases were used to find English-language articles on asthma and depression. Search terms included *asthma, depression, dysthymia, and mood.*

**Data Synthesis:** This literature suggests depressive symptoms are more common in asthma patients than in the general population and perhaps even more common than in some other general medical conditions. Depression may be associated with asthma morbidity and mortality. Limited data suggest the older tricyclic antidepressants may improve both depression and asthma symptoms. However, no studies have examined the use of second-generation antidepressants in asthma patients.

**Conclusion:** Depressive symptoms are common in asthma patients. However, the prevalence of depressive disorders in this population is not well determined. Future studies should focus on determining the prevalence of major depressive disorder in this population and the effect of antidepressants on mood and asthma symptoms.

Table 1. Prevalence of Depression in Asthma Patients

<table>
<thead>
<tr>
<th>Study and Authors</th>
<th>Study Group</th>
<th>Assessment</th>
<th>Outcome/Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dyer and Sinclair (1997)</td>
<td>40 elderly asthma patients</td>
<td>GDS</td>
<td>19/40 (48%) of asthma patients with GDS score &gt; 11; 11/40 (28%) of controls with GDS score &gt; 11 (p = .32)</td>
</tr>
<tr>
<td>Padur et al (1995)</td>
<td>25 children with asthma, 25 children with diabetes, 25 children with cancer, 25 controls</td>
<td>CDI</td>
<td>Asthma patients had significantly higher CDI scores compared with all other groups (p &lt; .05)</td>
</tr>
<tr>
<td>Badoux and Levy (1994)</td>
<td>102 adult asthma patients, 383 socially isolated patients, 252 controls</td>
<td>BSI</td>
<td>Higher BSI scores in asthma group than in controls (p &lt; .005)</td>
</tr>
<tr>
<td>Seigel and Golden (1990)</td>
<td>40 asthma patients, 40 controls</td>
<td>BDI</td>
<td>Higher BDI scores in asthma patients than in controls (p &lt; .001)</td>
</tr>
<tr>
<td>Lyketsos et al (1987)</td>
<td>35 adult asthma patients, 168 mixed-illness controls</td>
<td>SAD</td>
<td>Higher SAD depression scores in asthma patients than in controls (p = .02)</td>
</tr>
<tr>
<td>Teramaa (1979)</td>
<td>100 adolescent and adult asthma patients</td>
<td>BDI, MMPI</td>
<td>53% with BDI score &gt; 15</td>
</tr>
<tr>
<td>Meijer (1979)</td>
<td>31 children with asthma, 29 controls</td>
<td>Mother-Child Questionnaire (subscales of hostility, depression, anxiety, and defiance)</td>
<td>Asthma patients had higher depression scores compared with controls (p = .05)</td>
</tr>
<tr>
<td>Jones et al (1976)</td>
<td>147 adult asthma patients, 252 controls</td>
<td>MMPI</td>
<td>49% had elevated scores on hypochondriasis, depression, and hysteria triad (p &lt; .001)</td>
</tr>
</tbody>
</table>

Abbreviations: BDI = Beck Depression Inventory, BSI = Brief Symptom Inventory, CDI = Child Depression Inventory, GDS = Geriatric Depression Scale, MMPI = Minnesota Multiphasic Personality Inventory, SAD = Scale of Anxiety and Depression.

DATA SOURCES

A search of the MEDLINE (1966–1999) and PSYCHINFO (1967–1999) databases was conducted to find English-language studies and reviews investigating depression in asthma patients. Search terms included asthma, depression, dysthymia, and mood. We searched the bibliographies of these references to find additional research examining depression in asthma patients. Pertinent studies were divided into 3 categories: studies examining the prevalence of depressive symptoms in asthma patients, research assessing the effects of depression on the course of asthma, and research investigating the treatment of depression in asthma patients. In Table 1 (prevalence studies), we excluded studies with fewer than 50 subjects, since we felt inclusion of smaller studies would provide no useful data regarding depression prevalence. We also excluded studies published prior to 1975, since (1) their assessment techniques for depression were substantially different from those found in more recent studies and (2) diagnostic criteria for asthma have changed. Given the very small number of studies examining the use of antidepressants in asthma patients, we used less stringent inclusion criteria and discuss studies published prior to 1975.

RESULTS

Eight studies32–39 examining the prevalence of depressive symptoms in asthma patients met our inclusion criteria (see Table 1). Six of these were controlled studies,32–36,38 and all but 1 of these32 presented data consistent with a higher prevalence of depressive symptoms in asthma patients than in control groups. In the largest of the controlled studies, Badoux and Levy34 administered the Brief Symptom Inventory, a self-report questionnaire, to asthma patients (N = 102), normal controls (N = 252), and socially isolated individuals (N = 383) and found that asthma patients had significantly higher scores (p < .005) than normal controls, but lower scores than socially isolated individuals (p < .001). Lyketsos et al.36 found higher scores on the depression subscale of the Scale of Anxiety and Depression in asthma patients (N = 35) than in a group of controls with a variety of illnesses (N = 165), including alopecia, psoriasis, urticaria, irritable bowel syndrome, ulcers, ulcerative colitis, and hypertension. Only patients with rheumatoid arthritis (N = 37) had higher depression scores than the asthma patients. Dyer and Sinclair35 found no significant difference in prevalence of depressive symptoms (p = .32) in elderly asthma patients (N = 40) than in normal controls (N = 40). However, a much higher percentage of asthma patients than controls had elevated depression scores. Thus, the small sample size and resulting low statistical power may limit the certainty of these negative findings.

Three of the studies32,35,38 examined depressive symptoms in children and adolescents with asthma. Seigel and Golden35 found that adolescents with asthma (N = 40) had significantly higher Beck Depression Inventory (BDI) scores than did normal controls (p < .001) and scores similar to patients with sickle cell disease and diabetes. Since the subjects were relatively asymptomatic outpatients, the investigators suggested that the increase in depressive symptoms was not related to asthma symptoms. Padur et al.33 found significantly higher scores on the Child Depression Inventory in children with asthma (N = 25) than in children with diabetes (N = 25) or cancer (N = 25) or in healthy controls (N = 25). Meijer38 examined dependency and emotional disturbance in children...
with asthma (N = 31) and found that low-dependency boys with asthma had significantly more depressive symptoms (p = .05), as determined by the Mother-Child Questionnaire, than nonasthmatic low-dependency boys. Low-dependency girls with asthma also showed more depression than their high-dependency counterparts, but the difference was not significant.

Two uncontrolled studies, meeting the inclusion criteria and examining the prevalence of depression or depressive symptoms in asthma patients were also found. As with the controlled studies, both identified depressive traits or symptoms and did not diagnose depressive disorders. Jones et al. administered the Minnesota Multiphasic Personality Inventory (MMPI) to hospitalized adult asthma patients and found that 72/147 (49%) had elevated scores on the “neurotic triad” (scales of hypochondriasis, depression, and hysteria). Teiramaa, using the semistructured psychiatric interview along with the BDI and MMPI, identified depressive symptoms or a diagnosis of depressive neurosis in over half (53%) of the asthma subjects (N = 100).

### Relationship of Depression to Asthma Symptoms

Nine studies meeting our criteria assessed the relationship between depression and the course of asthma and are given in Tables 2 and 3. Three studies suggested that depression may increase risk of death from asthma (see Table 2). Strunk et al. examined 21 children who later died of asthma and a monitored control group. The group with fatal asthma showed evidence of greater “behavioral disturbance” (18/21 vs. 9/21; p > .01) and exhibited more depressive symptoms (16/21 vs. 9/21; p < .05). Picado et al. reported that 4/6 (66%) patients who died from asthma exacerbations required treatment for a “syndrome of anxiety-depression.” Interestingly, all 4 of the patients with depression who died had recently stopped taking prescribed psychotropic medication before the fatal attack. Mascia et al. retrospectively reviewed the psychological characteristics of severely asthmatic children admitted to the hospital over a 10-year period. Although not statistically significant, depressive symptoms were found in 77% (N = 9) of fatalities in this population while only 53% (N = 72) of survivors had depressive symptoms.

However, not all studies have found a consistent association between severity of asthma and depression (see Table 3). Yellowlees et al. examined patients with near-fatal asthma attacks (N = 13) and a control group with less severe illness (N = 36) and found a 33% overall prevalence rate of psychopathology in both groups. One subject in the study group (1/13, 8%) and one in the control group (1/36, 3%) were diagnosed with “depressive illness” according to DSM-III criteria, suggesting low rates of mood disorders in both groups.

Allen et al. suggested a possible etiologic link between depression and death from asthma. These investigators found that asthma patients with depression as indicated by scores derived from the Profile of Mood

### Table 2. Depression and Asthma-Related Death

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Group</th>
<th>Assessment</th>
<th>Outcome/Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mascia et al. (1989)</td>
<td>140 severe asthma patients</td>
<td>10-y patient chart review</td>
<td>Depressive symptoms were found in 48% with improved asthma vs 53% with no improvement and 77% of fatalities</td>
</tr>
<tr>
<td>Picado et al. (1989)</td>
<td>6 adult asthma patients</td>
<td>Patient chart review</td>
<td>In 4/6 (66%) of asthma fatalities, patients had recently stopped taking antidepressant medications</td>
</tr>
<tr>
<td>Strunk et al. (1985)</td>
<td>21 asthma patients</td>
<td>Patient chart review</td>
<td>Depressive symptoms in 16/21 (76%) of fatalities vs 9/21 (43%) of controls (p = .05)</td>
</tr>
</tbody>
</table>

### Table 3. Depression and Asthma Severity

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Group</th>
<th>Assessment</th>
<th>Outcome/Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rushford et al. (1998)</td>
<td>100 adult asthma patients</td>
<td>SDS</td>
<td>“Exaggerated perceivers” of asthma sympotms severity had higher scores on SDS (p = .026) than “normal perceivers”</td>
</tr>
<tr>
<td>Bosley et al. (1995)</td>
<td>72 adult asthma patients</td>
<td>HADS</td>
<td>Correlation found between depression and self-reported asthma symptoms (p &lt; .05); no correlation between depression and pulmonary function</td>
</tr>
<tr>
<td>Janson et al. (1994)</td>
<td>735 young adult patients</td>
<td>HADS</td>
<td>Higher POMS scores than controls (p = .07)</td>
</tr>
<tr>
<td>Allen et al. (1994)</td>
<td>11 asthma patients, 10 controls</td>
<td>POMS</td>
<td>Depression correlated with perceived severity (p &lt; .01), but no correlation with asthma severity/risk index scores</td>
</tr>
<tr>
<td>Janson-Bjerklie et al. (1992)</td>
<td>95 asthma patients</td>
<td>CES-D</td>
<td>1/13 (8%) with depression</td>
</tr>
<tr>
<td>Yellowlees et al. (1988)</td>
<td>13 patients with severe asthma (age, 18–68 y)</td>
<td>DSM-III, DIS</td>
<td>1/36 (3%) with depression</td>
</tr>
<tr>
<td></td>
<td>36 patients with less severe asthma</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

© Copyright 2000 Physicians Postgraduate Press, Inc.
Table 4. Antidepressant Therapy in Asthmatics

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Group</th>
<th>Assessment</th>
<th>Outcome/Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lechin et al (1998)</td>
<td>69 asthmatic children</td>
<td>Tianeptine (6 mg/d)</td>
<td>25% improvement in FEV1%</td>
</tr>
<tr>
<td>Wilson (1974)</td>
<td>Single case study</td>
<td>Perphenazine (6 mg/d)</td>
<td>Marked improvement of asthma and depression symptoms after 6 wk of medication therapy</td>
</tr>
<tr>
<td>Sanger (1969)</td>
<td>32 multiallergic patients</td>
<td>Amitriptyline (N = 16)</td>
<td>5/16 (31%) had moderate mood improvement (p = .20, NS)</td>
</tr>
<tr>
<td>Sugihara et al (1965)</td>
<td>60 children and adult asthma patients</td>
<td>Doxepin (N = 16)</td>
<td>12/16 (75%) had significant mood improvement (p = .006)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Am triptyline</td>
<td>62% with improvement in asthma symptoms rated as “good” or “excellent”</td>
</tr>
</tbody>
</table>

aAbbreviation: FEV1% = 1-second forced expiratory volume.

States questionnaire showed a 3-fold increased risk for an impaired voluntary drive to breathe when compared to euthymic asthma patients. Poor compliance with asthma treatment may also contribute to risk of a fatal attack. Bosley et al. found significantly higher scores (p < .05) on the depression subscale of the Hospital Anxiety and Depression Scale in patients who were noncompliant (N = 37) with their inhaled β-agonists and steroids than in those patients who were compliant with medication (N = 35).

Three studies suggested that depression might be related to increased asthma symptom reporting in a population-based study (N = 715), Janson et al. found a correlation between depression and self-reported asthma-related symptoms, but no correlation between a diagnosis of asthma and depression or objective asthma-related measurements (e.g., spirometry) and depression. Janson et al. Bjerklie et al. found that elevated scores on the Center for Epidemiologic Studies-Depression Scale were related to subjectively perceived asthma severity and danger, but not to objective asthma severity as indicated by medication, intubation history, and hospitalization frequency. Similarly, Rushford et al. found that “exaggerated perceivers” of asthma-related airflow obstruction had higher scores (p = .026) on the Self-Rated Depression Scale than “normal perceivers.”

Antidepressant Therapy in Asthma Patients

Four reports were found examining the use of antidepressants in asthma patients (Table 4). Two of these studies examined the efficacy of antidepressants in treating asthma-related symptoms in nondepressed patients. Sugihara et al. administered amitriptyline to 60 asthma patients, finding a “good” to “excellent” response in asthma symptoms in 62% of the subjects. The best response (79%) was observed in children under 15 years of age (N = 14). In a double-blind crossover design, Lechin et al. observed a mean improvement of 25% in 1-second forced expired volume (FEV1% rates) in children with asthma (N = 69) treated with the selective serotonin reuptake enhancer tianeptine.

Two reports of improvement in mood in depressed asthma patients given antidepressants were found. Sanger compared amitriptyline and doxepin in a randomized double-blind study investigating the treatment of anxiety and depression in patients with multiple allergies, including dermatologic conditions, hay fever, and bronchial asthma. Doxepin was significantly more effective than amitriptyline at reducing Hamilton Rating Scale for Depression scores in this population. Overall, 12 of 16 doxepin-treated patients reportedly showed moderate-to-marked improvement in their overall scores, whereas 5 of 16 amitriptyline-treated patients showed moderate improvement at best. The potent antihistamine effects of doxepin, which ameliorate allergic reactions and promote bronchodilation, may in part explain the greater improvement in emotional symptoms with doxepin.

Wilson reported the case of a 48-year-old female patient who suffered from asthma symptoms until she was given a combination of perphenazine (6 mg/day) and amitriptyline (30 mg/day) for anxiety and depression. After taking this regimen for 6 weeks, the patient reported that her asthma medications were discontinued and that her asthma remained in remission during the 3-month assessment period.

DISCUSSION

Virtually all studies suggest that depressive symptoms are more common in asthma patients than in the general population. Since only one study examined the prevalence of MDD rather than depressive symptoms, the rates of formal mood disorders in asthma patients cannot be assessed. Minimal data were found comparing the prevalence of depression in asthma with that in other chronic illnesses. The available studies suggest rates of depressive symptoms may be more common in asthma than in some other severe illnesses. However, the presence of depressive disorders, not symptoms, is the basis for psychiatric diagnosis and treatment. Thus, given the available data, the prevalence of clinically significant depression in asthma patients cannot be determined.

One limitation in studies examining depressive symptoms in medically ill populations is the possibility of increased scores on depression measures due to the physical symptoms of the illness. Asthma symptoms can cause
insomnia and asthma medications (e.g., β-agonists) can cause anxiety; both of these symptoms elevate scores on some depression scales. However, the elevated scores on the BDI, which emphasizes psychological rather than neurovegetative symptoms of depression, reported by Seigel and Golden 35 and Teiramaa et al. 37 suggest that asthma symptoms alone do not fully explain the elevated depression scores generally observed.

Data from external studies may provide evidence supporting a possible biological link between asthma and depression. Flinders line rats are very sensitive to the effects of cholinergic agents and exhibit depressive behavior in some animal models of depression.33 This breed of rat also exhibits airway hyperresponsiveness after exposure to allergens. 34 In human studies, a subset of asthma patients55,56 as well as a subset of persons with depression exhibit evidence of glucocorticoid resistance. 5,58 Additional controlled studies are needed, examining the prevalence of depression in asthma patients and persons with comparable disability from other general medical conditions, to determine if asthma patients are at increased risk of depression compared with other general medical conditions.

Data on the effect of depression on asthma are mixed, with some studies suggesting poor compliance with care, more severe airway obstruction, and even increased risk of asthma-related deaths in depressed asthma patients than nondepressed asthma patients. The association of depression with asthma-related mortality is of particular concern. However, these studies have methodological limitations, including retrospective designs and small sample sizes. If confirmed, the increased mortality risk may be consistent with data suggesting increases in cholinergically mediated airway constriction associated with stress or negative mood states. 39-41 However, other data suggest that depressed patients subjectively perceive themselves as having more severe asthma symptoms than euthymic patients, but this perception is not supported by objective measures of disease severity. 43,45,47 In addition, preliminary data from our group suggest less severe airway obstruction, as measured with spirometry, in asthma patients with a history of a mood disorder than in those without a mood disorder. 52 Thus, asthma patients with depression may see themselves as having more severe asthma, which could lead these patients to seek further health care treatment. A greater number of emergency room visits, greater frequency of appointments, and more aggressive treatment in the depressed asthmatic potentially could lead to an improvement in symptoms, but also greater cost due to overutilization of medical services. One possible explanation for the seemingly dichotomous findings of increased risk of death and exaggerated perception of asthma symptoms is that there may be 2 subsets of depressed asthma patients: a group with severe asthma in which depression may lead to poor medication compliance and an increased risk of mortality, and a second group with mild asthma and symptoms of anxiety, depression, and somatic complaints who may tend to utilize medical services more often (e.g., emergency rooms).

In contrast to data in other chronic diseases, such as diabetes mellitus, few studies in the current medical literature report the effects of treatment of depression in asthma patients. These include a single case report 50 and one small uncontrolled study 51 that used antidepressants infrequently prescribed in current practice. Even though several clinical trials suggest that antidepressants may improve both physical and psychological symptoms in other general medical conditions, there has been no clinical trial using second-generation antidepressants (e.g., selective serotonin reuptake inhibitors) to treat depression in asthma patients. Clearly, clinical trials of antidepressant agents are needed in asthma patients and will allow comparisons to be made among depressive symptoms, medication compliance, and both objective and subjective measures of disease severity.

CONCLUSION

In summary, the relationship of depression to asthma symptoms has been the topic of surprisingly little investigation. Given data which suggest that asthma prevalence, morbidity, and mortality are increasing and evidence that suggests an association between depression and asthma-related deaths, further research in the area is needed. Since antidepressant therapy is associated with both improvement in mood and physical symptoms in other general medical conditions, clinical trials are needed in asthma patients using both depressive symptoms and asthma symptoms as outcome measures.

**Drug names:** amitriptyline (Elavil and others), doxepin (Sinequan and others), nortriptyline (Pamelor and others), perphenazine (Trilafon and others).

**REFERENCES**


8. Simon GE, VonKorff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry 1995;52:850–856

medical and psychiatric practices. Arch Gen Psychiatry 1985;12: 1164–1170
22. Gill D, Hatcher S. A systematic review of the treatment of depression with antidepressant drugs in patients who also have a physical illness. J Psychosom Res 1990;34:131–143
29. Weiss KB, Wagener DK. Changing patterns of asthma mortality identifying target populations at high risk. JAMA 1992;268:1683–1687
37. Teiramaa E. Psychosocial and psychic factors and age at onset of asthma. J Psychosom Res 1979;23:37–37
42. Strunk RC, Mazurek DA, Fuhrmann GS, et al. Physiologic and psychologic characteristics associated with deaths due to asthma in childhood. JAMA 1985;254:1193–1198
44. Bosley CM, Fosbury JA, Cochrane GM. The psychological factors associated with poor compliance with treatment in asthma. Eur Respir J 1995;8: 899–904
56. Leung DY, Spahn JD, Siegel SJ. Immunologic basis and management of steroid-resistant asthma. Allergy Asthma Proc 1999;20:49–19